MedTrace Logo

Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

NCT07690891 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-07-08

No results posted yet for this study

Summary

This is a single-arm, open-label Phase 2 study designed to evaluate the treatment outcomes of nemtabrutinib-venetoclax-obinutuzumab as a frontline management for chronic lymphocytic leukemia (CLL).

Conditions

Interventions

DRUG

Nemtabrutinib

45 mg daily for 15 28-day cycles.

DRUG

Venetoclax

Cycle 4, Days 1-7: 20 mg; Cycle 4, Days 8-14: 50 mg; Cycle 4, Days 15-21: 100 mg; Cycle 4, Days 22-28: 200 mg; Cycle 5-15: 400 mg.

DRUG

Obinutuzumab

Cycle 4, Day 1: 100 mg; Cycle 4, Day 2: 900 mg; Cycle 4, Day 8: 1000 mg; Cycle 4, Day 15: 1000 mg; Cycles 5-9, Day 1: 1000 mg.

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Guru S Guru Murthy, MD · Medical College of Wisconsin

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-01
Primary Completion
2029-12-01
Completion
2031-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07690891 on ClinicalTrials.gov